|
Senior Public Office Holders who were lobbied in this activity:
|
Penny Ballem,
Senior Advisor
Office of the Premier
Hon. Adrian Dix,
Minister
Health
David Eby,
Premier
Premier,
Office of the Premier
Matt Smith,
Chief of Staff
Office of the Premier
|
Subject Matter of the Lobbying Activity
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
Discussions regarding pharmaceutical and vaccine procurement, drug and vaccine listings on publicly funded programs and other issues related to access to GSK medicines
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
COVID-19, Economic Development and Trade, Finances and Budgets, Government Procurement, Health, Industry
|
GSK will conduct activities related to advancement of GSK medicines and vaccines with stakeholders of the healthcare system.
|
- Development of any legislative proposal by the government of British Columbia, a Provincial entity or a member of the Legislative Assembly
- Introduction, amendment, passage or defeat of any Bill or resolution in or before the Legislative Assembly
- Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
- Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
COVID-19, Economic Development and Trade, Finances and Budgets, Health, Hospitals, Industry
|
Meeting with Government and Healthcare officials to discuss pharmaceutical and health policy, economic development as it relates to clinical trials and other research, scientific information related to GSK's portfolio of medicines and vaccines.
|
- Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
COVID-19, Economic Development and Trade, Health, Hospitals, Intellectual Property, Science and Technology
|
|